employed BGI Stereo‐seq to analyse four ER+HER2– breast cancer samples (two endocrine‐sensitive and two endocrine‐resistant) from patients undergoing endocrine therapy post‐surgery and chemotherapy. This evidence concerns the gene ERBB2 and breast carcinoma.